Non-invasive prenatal testing (NIPT) is a DNA test on maternal blood to screen pregnancies for the most common fetal chromosome anomalies such as trisomy 21 that is Down syndrome, trisomy 18 Edwards syndrome and trisomy 13 Patau syndrome. Whereas NIPT can also determine the gender of the fetus and NIPT is highly reliable in over 99% of Down syndrome cases. The results of the NIPT screening can help doctor to decide the next steps, including whether to have a diagnostic test like chorionic villus sampling (CVS) or collected from the amniotic fluid or placenta, to make sure whether a baby has a chromosome abnormality. Non-invasive prenatal testing can be performed any time after 9 weeks into your pregnancy earlier than any other prenatal screening or diagnostic test.

During non-invasive prenatal testing DNA from the mother and fetus is extracted from maternal blood sample and it is recommended for women who have risk factors for having a baby who has a chromosomal condition and this risk factor may include older maternal age or previously given birth to a baby who has Down syndrome, trisomy 13 or trisomy 18. Non-invasive prenatal testing is also recommended if a woman have an Rh negative blood type because if the fetus is Rh positive, mother might produce Rh antibodies after exposure to fetal red blood cells. This is not a concern during a first pregnancy, but during subsequent pregnancies. These factors are expected to provide major growth traction to the global non-invasive prenatal testing market.

Global Non-invasive Prenatal Testing (NIPT) Market - Dynamics

Increasing launches and approvals of new non-invasive prenatal tests (NIPT) is one of the factor which drives the market growth in near future. For instance, in November 2019, F. Hoffmann-La Roche Ltd., received approval from Health Canada for its non-invasive prenatal test, Harmony Test. The Harmony Test is designed to screen the trisomy 21 (Down syndrome) and other common fetal aneuploidies.

Furthermore, increasing prevalence of chromosomal disorder is expected to propel the market growth over the forecast period. According to Centers for Disease Control and Prevention (CDC) in year 2016, Down syndrome continues to be the most common chromosomal disorder, as each year about 6000 babies were born with Down syndrome in the U.S.

Global Non-invasive Prenatal Testing (NIPT) Market - Regional Insights

North America held the dominant position in 2019, in the global non-invasive prenatal testing (NIPT) market, owing to launch and approvals of new non-invasive prenatal tests (NIPT). For instance, in August 2019, Axia Women’s Health, a U.S. based independent women’s healthcare group, launched non-invasive prenatal testing (NIPT) in U.S. OB/GYN physician-owned laboratory. Axia’s Precision Prenatal NIPT screens for Down syndrome, Edwards syndrome, Patau syndrome, Triploidy, Monosomy X, and sex-chromosome aneuploidies.

Europe is also showcasing the high growth in non-invasive prenatal testing (NIPT) market due to increased launches and approvals of new non-invasive prenatal tests. For instance, in October 2019, BillionToOne, Inc., a diagnostics company, and Eluthia, a European based genetic diagnostic tests provider, announced the launch of UNITY test, a non-invasive prenatal test, in the European region. UNITY test is designed to screen autosomal-recessive conditions such as cystic fibrosis, spinal muscular atrophy (SMA), sickle cell disease and other hemoglobinopathies. Eluthia will be providing UNITY screen in Germany, Austria, Switzerland and the Netherlands.

Global Non-invasive Prenatal Testing (NIPT) Market - Competitive Landscape

Some of the key players operating in the global non-invasive prenatal testing (NIPT) market include GE Healthcare, Koninklijke Philips N.V., Illumina, Inc., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., BillionToOne, Inc., Pacific Biosciences of California, Inc., PerkinElmer, Inc., QIAGEN N.V., Agilent Technologies, Inc., and Beijing Genomics Institute.

Global Non-invasive Prenatal Testing (NIPT) Market - Market Taxonomy

On the basis of product type, the global non-invasive prenatal testing (NIPT) market is segmented into:

  • Assay Kits & Reagents
  • Consumables
  • Disposables
  • Next-Generation Sequencing System
  • Instruments
  • PCR Instruments
  • Ultrasound Devices
  • Microarrays
  • Other Instruments

On the basis of method, the global non-invasive prenatal testing (NIPT) market is segmented into:

  • Ultrasound Detection
  • Cell-free DNA in Maternal Plasma Tests
  • Biochemical Screening Tests
  • Fetal Cells in Maternal Plasma Tests

On the basis of applications, the global non-invasive prenatal testing (NIPT) market is segmented into:

  • Trisomy
  • Micro deletion Syndrome
  • Other Application

 On the basis of end user, the global non-invasive prenatal testing (NIPT) market is segmented into:

  • Diagnostic Laboratories
  • Hospitals

On the basis of region, the global non-invasive prenatal testing (NIPT) market is segmented into:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
N/A
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner